Eva Ciruelos Gil

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Aditya Bardia, Sara M. Tolaney, Kevin Punie et al. · Annals of Oncology · 2021 · 299 citations · Full text

Medicine, Oncology, Pharmacology +16

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Defining the optimal sequence for the systemic treatment of metastatic breast cancer

Joan Albanell Mestres, A. B. iMolins, Eva Ciruelos Gil et al. · Clinical & Translational Oncology · 2016 · 25 citations · Full text

Medicine, Oncology, Breast Oncology +15

Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Sara A. Hurvitz, Sara M. Tolaney, Kevin Punie et al. · Cancer Research · 2021 · 18 citations

Medicine, Oncology, Pharmacology +17